Publication: Cost-effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancer
Issued Date
2006-05-01
Resource Type
ISSN
01252208
01252208
01252208
Other identifier(s)
2-s2.0-33646759975
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.89, No.5 (2006), 690-698
Suggested Citation
Supon Limwattananon, Chulaporn Limwattananon, Savitree Maoleekulpairoj, Noppadol Soparatanapaisal Cost-effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancer. Journal of the Medical Association of Thailand. Vol.89, No.5 (2006), 690-698. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/23756
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cost-effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancer
Other Contributor(s)
Abstract
An economic evaluation of paclitaxel added subsequently to doxorubicin plus cyclophosphamide (AC) adjuvant therapy for early breast cancer with lymph nodes positive is presented. Health care cost associated with AC alone vs. AC with paclitaxel was compared under Thai health care context. Based on CALGB9344, paclitaxel increased the disease-free survival (DFS) by 17%. Based on Markov simulation for 15 years, paclitaxel prolonged the patient's life by 0.30 quality-adjusted life years (QALY). Such an increased effectiveness was off set by the adjuvant cost net of recurrence, follow-up, and terminal care by 221,433 Baht. This means an additional year of perfect health gained by paclitaxel is achieved through an incremental cost of 738,111 Baht. Such an incremental cost-effectiveness ratio (ICER) is beyond the threshold recommended by World Health Organization. In women with negative estrogen receptor that DFS was improved to 28%, the ICER of paclitaxel was reduced to 393,984 Baht per QALY.